PeptiSystems Announces Major Investment for Growth
PeptiSystems, a pioneering life science company known for its innovative manufacturing solutions in peptide and oligonucleotide-based therapeutics, has secured a significant growth equity investment from Rubicon Healthcare Partners. This partnership is set to propel PeptiSystems into a new phase of global expansion, enabling the company to enhance its cutting-edge manufacturing capabilities to meet the surging demands in the biopharmaceutical sector.
Empowering Commercial Development
Rubicon Healthcare Partners is a forward-thinking investment firm dedicated to supporting Nordic life science enterprises that provide essential products and services to the healthcare and biopharmaceutical arenas. With this alliance, PeptiSystems will gain access to Rubicon’s vast experience and extensive network, invaluable assets for advancing its international presence and strategic initiatives. Following the investment, Rubicon will emerge as the largest stakeholder in PeptiSystems, underscoring their commitment to the company's vision.
Strategic Growth Initiatives
This new influx of capital is poised to significantly enhance PeptiSystems’ commercial advancement. As the company continues to build upon its growing customer base and momentum in the market, it is now focusing on large-scale industrial applications. PeptiSystems aims to assist its customers in transitioning to Good Manufacturing Practice (GMP) production of therapeutic peptides and oligonucleotides, positioning itself as a leader in the field.
Leadership Perspectives on the Investment
“We are thrilled to welcome Rubicon Healthcare Partners as a shareholder in PeptiSystems. Their vast expertise in the global life science landscape and strong Nordic presence will serve as crucial assets as we scale our technology for industrial applications,” stated Karin Granath, CEO of PeptiSystems. She underlined that this investment reflects confidence in their team and strategy to capitalize on the rapid growth of the biopharma market.
Commitment to Excellence
Ole J. Dahlberg, Managing Partner at Rubicon, expressed enthusiasm about being part of PeptiSystems' journey, emphasizing their strong values, focus on excellence, and a strategic vision that resonates with Rubicon's investment philosophy. He praised PeptiSystems' innovative portfolio and customer-centric approach as key attractions for their partnership.
Chairman's Insights
Mats Johnson, Chairman of the Board for PeptiSystems, remarked, “We are excited to have Rubicon come on board as a major shareholder. This financial investment significantly enhances our ability to accelerate growth and further establish our unique flow-through technology aimed at producing therapeutic peptides and oligos.”
Next Steps and Closing Conditions
The transaction is subject to standard closing conditions, which includes a review under Sweden's Foreign Direct Investment screening legislation. This diligent process ensures that the investment aligns with regulatory standards while safeguarding the company's integrity and future growth.
Contact Information
For further inquiries regarding this investment announcement, please reach out to:
Karin Granath, CEO, PeptiSystems
Phone: +46 702 82 07 47
Ole J. Dahlberg, Managing Partner, Rubicon Healthcare Partners
Frequently Asked Questions
What is the purpose of the investment from Rubicon Healthcare Partners?
The investment aims to accelerate PeptiSystems' global expansion and enhance their manufacturing solutions for peptide and oligonucleotide-based therapeutics.
Who will be the largest shareholder in PeptiSystems after this investment?
Rubicon Healthcare Partners will become the largest shareholder following the completion of this transaction.
What does PeptiSystems specialize in?
PeptiSystems specializes in advanced manufacturing solutions for peptide and oligonucleotide-based therapeutics, focusing on innovative production technologies.
How does this partnership benefit PeptiSystems?
The partnership provides PeptiSystems access to Rubicon's expertise and networks, crucial for their international expansion and strategic development.
What are the next steps for PeptiSystems after this announcement?
PeptiSystems will focus on accelerating its commercial development and supporting customers in transitioning to GMP production of therapeutic products.
